Content available at: https://www.ipinnovative.com/open-access-journals

IP International Journal of Comprehensive and Advanced Pharmacology

Journal homepage: www.ijcap.in

Short Communication

GD2 CAR T-cell therapy for diffuse midline gliomas: A paradigm shift in treatment

Neha R. Raghani[1], Mehul R. Chorawala[2*], Prasad C. Kote[3], Bhupendra G. Prajapati[4]

[1]Dept. of Pharmacology and Pharmacy Practice, Saraswati Institute of Pharmaceutical Sciences, Gandhinagar, Gujarat, India

[2]Dept. of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Opp. Gujarat University, Navrangpura, Ahmedabad, Gujarat, India

[3]Dept. of Pharmaceutics, Ashok College of Pharmacy, Ashok Gramin Shikshan Sanstha, Ashoknagar, Shrirampur, Ahmednagar, Maharashtra, India

[4]Dept. of Pharmaceutics and Pharmaceutical Technology, Shree S. K. Patel College of Pharmaceutical Education & Research, Ganpat University, Mehsana, Gujarat, India

Abstract

Diffuse midline gliomas (DMGs), including diffuse intrinsic pontine gliomas (DIPGs), are highly aggressive brain tumours with limited treatment options and poor prognosis. Standard therapies, such as radiation and chemotherapy, offer only marginal survival benefits. Chimeric antigen receptor (CAR) T-cell therapy targeting disialoganglioside GD2 has emerged as a novel immunotherapeutic approach, leveraging its high expression on DMG cells. Preclinical and early clinical studies have demonstrated promising antitumor activity, with GD2 CAR T-cells successfully trafficking into the central nervous system and inducing tumour regression. However, challenges such as the immunosuppressive tumour microenvironment, potential neurotoxicity, and optimal delivery strategies remain. This short communication explores the rationale, recent advances, and ongoing challenges of GD2 CAR T-cell therapy in DMGs. While further research is needed, GD2-directed CAR T-cell therapy holds significant potential to transform the treatment landscape and improve outcomes for patients with these devastating tumours.

Keywords: Diffuse midline gliomas (DMGs); CAR T-cell therapy; Disialoganglioside GD2.

Received: 26-02-2025; **Accepted:** 01-04-2025; **Available Online**: 07-04-2025

1. Introduction

Diffuse midline gliomas (DMGs), including diffuse intrinsic pontine gliomas (DIPGs), represent some of the most aggressive and fatal brain tumours, predominantly affecting children and young adults. These tumours are characterized by their diffuse infiltration of critical brainstem and midline structures, making surgical resection nearly impossible. Radiation therapy remains the current standard of care, offering only transient relief, while chemotherapeutic and targeted treatment options have shown limited efficacy. Despite decades of research, the prognosis for DMGs remains dismal, with a median survival of approximately 9-12 months post-diagnosis.[1] Recent advances in immunotherapy, particularly chimeric antigen receptor (CAR) T-cell therapy, have sparked new hope for DMG patients.[2] CAR T-cell therapy involves genetically modifying a patient's T-cells to recognize and attack tumour-specific antigens. One such promising target is disialoganglioside GD2, a surface antigen highly expressed on DMG cells but with limited expression in normal brain tissues.[3] The rationale for targeting GD2 stems from its successful application in neuroblastoma, where GD2-directed CAR T-cell therapy has demonstrated significant antitumor activity.[4]

Preclinical studies[5-9] and early-phase clinical trials[10-13] have provided compelling evidence that GD2 CAR T-cells can effectively penetrate the central nervous system (CNS) and induce tumour regression in DMG models. Encouragingly, initial patient trials have shown prolonged survival and improved quality of life in some cases. However, challenges remain, including overcoming the immunosuppressive tumour microenvironment, mitigating potential neurotoxicity, and optimizing delivery methods.[11,13-15] This short communication explores the rationale behind GD2 CAR T-cell therapy for DMGs,

*Corresponding author: Mehul R. Chorawala
Email: mehulchorawala@gmail.com

https://doi.org/10.18231/j.ijcaap.2025.010

highlights recent advancements, and discusses the key challenges that need to be addressed for this promising treatment to become a viable therapeutic option. As research progresses, GD2-targeted CAR T-cell therapy may herald a new era in neuro-oncology, offering a long-awaited breakthrough for patients with these devastating tumours.

2. GD2 as a Target in DMG

Disialoganglioside GD2 is a well-established antigen overexpressed in various neuroectodermal tumours, including neuroblastoma. Its high expression in DMGs, particularly H3K27M-altered or mutant gliomas, makes it an attractive immunotherapeutic target. Unlike other tumor antigens, GD2 is expressed at minimal levels in normal brain tissues, reducing the risk of off-target toxicity.[16] Several recent studies[9-13] have provided compelling evidence that GD2 CAR T-cells can effectively target and eliminate DMG cells, raising hopes for a breakthrough therapy (**Figure 1**).



Figure 1: Schematic representation of GD2 CAR *T-cell therapy in glioblastoma*

The **Figure 1** illustrates the administration of GD2-targeted chimeric antigen receptor (CAR) T cells, their recognition of GD2-expressing glioblastoma cells, and subsequent tumour cell lysis through immune activation. This approach highlights the potential of GD2 CAR T-cell therapy in targeting glioblastoma, a highly aggressive brain tumour with limited treatment options.

3. Preclinical and Clinical Advances

Initial preclinical models demonstrated that GD2-targeting CAR T-cells could traffic efficiently into the central nervous system (CNS) and exert potent antitumor effects against DMG cells.[5-8] Encouragingly, recent clinical trials evaluating GD2 CAR T-cell therapy have reported promising responses.[10-13] In a pioneering study by Mount Christopher and colleagues (2018), GD2 CAR T-cells were infused intraventricularly in pediatric patients with DMG, demonstrating tumour regression and prolonged survival in select cases.[9] Another trial conducted by Stanford University highlighted the feasibility and safety of repeated GD2 CAR T-cell infusions, showing partial responses and improved quality of life in treated patients.[11]

4. Challenges and Future Directions

While GD2 CAR T-cell therapy represents a promising innovation, several challenges remain. One significant hurdle is the immunosuppressive tumour microenvironment (TME) of DMGs, which can dampen CAR T-cell activity.[16,17] Strategies to overcome TME-mediated resistance include engineering CAR T-cells with resistance to inhibitory cytokines or co-administering checkpoint inhibitors.[18] Additionally, optimizing the route of administration – whether intraventricular, intratumoral, or systemic – remains an area of active investigation to enhance therapeutic efficacy and limit systemic toxicity.[19] Another major concern is the potential for neurotoxicity, including inflammation-induced cerebral edema.[15] While initial trials suggest that GD2 CAR T-cell therapy is relatively safe with manageable side effects, further research is required to refine dosing regimens and mitigate adverse events.

5. Conclusion

The advent of GD2 CAR T-cell therapy for DMGs represents a paradigm shift in the treatment of these lethal tumours. Although challenges persist, early clinical successes offer a glimmer of hope for patients who previously had no viable therapeutic options. Continued research, refinement of CAR T-cell engineering, and combination strategies with other immunotherapies may pave the way for a future where DMGs are no longer a terminal diagnosis. With ongoing clinical trials and advancements in immunotherapy, GD2 CAR T-cell therapy could potentially redefine the landscape of neuro-oncology and provide a lifeline for patients battling DMGs.

6. Source of Funding

None.

7. Conflict of Interest

None.

References

1. Noon A, Galban S. Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas. *Neoplasia*. 2023;40:100899. doi: 10.1016/j.neo.2023.100899.
2. Prapa M, Chiavelli C, Golinelli G, Grisendi G, Bestagno M, Di Tinco R, et al. GD2 CAR T cells against human glioblastoma. *NPJ Precis Oncol*. 2021;5(1):93.

3. Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. *Front Oncol*. 2020;10:1000.
4. de Billy E, Pellegrino M, Orlando D, Pericoli G, Ferretti R, Businaro P, et al. Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant. *Neuro Oncol*. 2022;24(7):1150–63.
5. Murty S, Haile ST, Beinat C, Aalipour A, Alam IS, Murty T, et al. Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model. *Oncoimmunology*. 2020;9(1):1757360.
6. Gargett T, Ebert LM, Truong NTH, Kollis PM, Sedivakova K, Yu W, et al. GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma. *J Immunother Cancer*. 2022;10(9):e005187.
7. Nehama D, Di Ianni N, Musio S, Du H, Patané M, Pollo B, et al. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. *EBioMedicine*. 2019;47:33–43.
8. Zhou D, Zhu X, Xiao Y. Advances in CAR-T therapy for central nervous system tumors. *Biomark Res*. 2024;12(1):132.
9. Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. *Nat Med*. 2018;24(5):572–9.
10. Lin FY, Stuckert A, Tat C, White M, Ruggieri L, Zhang H, et al. Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. *J Clin Oncol*. 2024;42(23):2769–79.
11. Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. *Nature*. 2022;603(7903):934–41.
12. Liu Z, Zhou J, Yang X, Liu Y, Zou C, Lv W, et al. Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma. *Mol Cancer*. 2023;22(1):3.
13. Monje M, Mahdi J, Majzner R, Yeom KW, Schultz LM, Richards RM, et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. *Nature*. 2025;637(8046):708–15.
14. Luksik AS, Yazigi E, Shah P, Jackson CM. CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression. *Cancers (Basel)*. 2023;15(5):1414.
15. Mahdi J, Dietrich J, Straathof K, Roddie C, Scott BJ, Davidson TB, et al. Tumour inflammation-associated neurotoxicity. *Nat Med*. 2023;29(4):803–10.
16. Machy P, Mortier E, Birklé S. Biology of GD2 ganglioside: implications for cancer immunotherapy. *Front Pharmacol.* 2023;14:1249929.
17. Guzman G, Pellot K, Reed MR, Rodriguez A. CAR T-cells to treat brain tumors. *Brain Res Bull*. 2023;196:76–98.
18. Glover M, Avraamides S, Maher J. How Can We Engineer CAR T Cells to Overcome Resistance? *Biologics*. 2021;15:175–98.
19. Upreti D, Bakhshinyan D, Bloemberg D, Vora P, Venugopal C, Singh SK. Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumours. *Front Immunol*. 2020;11:599253.

Cite this article: Raghani NR, Chorawala MR, Kote PC, Prajapati BG. GD2 CAR T-cell therapy for diffuse midline gliomas: A paradigm shift in treatment. *IP Int J Compr Adv Pharmacol*. 2025;10(1):72–74.